
Seoul Bio Hub announced that it is recruiting the first batch of companies to move into the 'Hongneung Bio-Medical R&D Anchor Facility', which is being established by the Seoul Metropolitan Government and jointly operated by the Korea Institute of Science and Technology (KIST) and Korea University in 2025.
This recruitment is aimed at activating startups and fostering promising startups in the bio and medical industries, and applications for occupancy will be accepted until May 20. Selected companies will be housed in one of three facilities: the Seoul Bio Hub main building, Seoul Bio Innovation Community Center, and BT-IT Convergence Center.
The Seoul Bio Hub and Innovation Community Center are open to startups that have been in business for less than 5 years, prospective entrepreneurs, and research institutes affiliated with companies that have excellent technology or ideas in the so-called “red bio” fields such as pharmaceuticals, medical devices, and digital healthcare. The BT-IT Convergence Center is open to companies specializing in digital healthcare.
The basic period of residence is 1 year, and can be extended in 1-year increments for up to 3 years through extension review.
Various benefits are provided to companies that move in, including ▲support for space and shared facilities ▲benefits for companies in the Seoul Hongneung Research and Development Special Zone ▲support for attracting investment and promoting companies ▲priority provision of Seoul City startup support services ▲use of shared research equipment ▲opportunities to link with academia-research innovation networks ▲specialized education in the red bio field ▲support for utilizing hospital-based medical data, etc.
A Seoul Bio Hub official said, “Hongneung is a representative domestic bio innovation cluster, and it has the foundation necessary for companies located there to strengthen their technological competitiveness and advance into the global market,” adding, “We look forward to the active participation of startups with innovative capabilities.”
- See more related articles
You must be logged in to post a comment.